Tenet Flags $450 Million Of One-Time Conifer EBITDA In 2026, Still Sees 2027 Growth

The hospital operator says the $450 million of adjusted EBITDA from Conifer transitions won't repeat, yet it expects growth next year.

Share
Tenet Flags $450 Million Of One-Time Conifer EBITDA In 2026, Still Sees 2027 Growth

Tenet Healthcare expects Conifer transition activities to add $450 million of adjusted EBITDA in 2026 and does not expect that to recur in 2027, Chairman and CEO Saumya Sutaria said on the company's third-quarter earnings call Thursday. Even so, he said, the company expects its overall adjusted EBITDA to grow next year once the Conifer effect is stripped out.

Bridging 2026 to 2027

Tenet, a Dallas-based healthcare services company that runs hospitals, outpatient facilities and the USPI surgery-center business, is selling the contract work tied to its Conifer unit. Sutaria called the $450 million an estimate that depends on how the transitions proceed operationally, and said Tenet will update it after fourth-quarter results.

A Bank of America analyst asked whether Conifer was the only item to remove. CFO Sun Park answered that Tenet believes it will grow total EBITDA next year once it normalizes for the $450 million of one-time transition items.

Sutaria said the 2027 view assumes currently known regulatory frameworks. Tenet is still sizing further potential exchange headwinds and the estimated impact of Medicaid work requirements, and details will come after the fourth quarter as usual. He said USPI should not be materially affected by those two items.

Park told a Leerink Partners analyst that about $160 million of the $450 million falls between the third and fourth quarters and is weighted to the second half. A big portion of the rest, tied to the contract's contribution this year, is spread relatively evenly through the year.

A raised outlook and a $147 million boost

Third-quarter net operating revenues were $5.6 billion and consolidated adjusted EBITDA was $1.355 billion, Sutaria said. Adjusted earnings per share rose 80% to $6.64. Excluding $147 million of contract-transition items that were not in prior guidance, adjusted EBITDA grew 10% from a year earlier at a 21.8% margin.

Park said the $147 million has two parts: a $97 million revenue timing shift between the third and fourth quarters that does not change full-year revenue, and $50 million of EBITDA from transition activities, including expense cuts that came earlier than planned.

Tenet raised its 2026 adjusted EBITDA guidance to $5.05 billion to $5.2 billion, up $195 million at the midpoint. Sutaria said more than 40% of the increase reflects fundamental outperformance. Revenue guidance is now $22.05 billion to $22.45 billion, and adjusted free cash flow after minority interests is guided to $1.925 billion to $2.155 billion, which includes about $150 million of Conifer-related tax payments.

Sutaria said the total value generated by the Conifer sale now rises to about 15 times 2025 adjusted EBITDA minus noncontrolling interests.

Buybacks and balance sheet

Tenet bought back 970,000 shares for $255 million in the quarter and 8 million shares for $1.615 billion so far this year. It ended September with $2.67 billion of cash and no borrowings on its credit line. It also swapped $2 billion of notes due in 2027 and 2028 for new notes maturing in 2034, leaving no significant debt maturities until 2028.

Exchange admissions and revenue fell 18% from a year earlier, Park said, and made up about 5.5% of net operating revenues. USPI adjusted EBITDA rose to $537 million, with same-facility revenue up 4.5%.

Tenet's market value was $21.6 billion in Thursday morning trading, and Sutaria said the company remains committed to returning free cash flow through repurchases.

Sources

More on Tenet Healthcare

All Tenet Healthcare (THC) coverage →